MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Cytosorbents Corporation EBITDA 2011-2026 | CTSO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cytosorbents Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.5 M | -15.1 M | -30.5 M | -5.47 M | -8.83 M | -1.97 M | -18.4 M | -15.2 M | -9.62 M | -11.3 M | -9.19 M | -7.21 M | -4.65 M | -3.44 M | -4.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.97 M | -30.5 M | -10.6 M |
Quarterly EBITDA Cytosorbents Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.56 M | - | -3.52 M | - | -4.53 M | - | -4.26 M | - | - | - | -7.63 M | - | -8.36 M | -8.36 M | -7.57 M | -9.56 M | -4.89 M | -4.92 M | -2.7 M | -2.63 M | -1.46 M | -2.96 M | -2.3 M | -5.43 M | -5.21 M | -3.35 M | -4.15 M | -5.59 M | -2.45 M | -4.07 M | -3.04 M | -3.81 M | -1.99 M | -2.23 M | -1.49 M | -4.57 M | -2.03 M | -2.62 M | -2.06 M | -2.21 M | -2.07 M | -2.18 M | -2.69 M | -2.89 M | -1.41 M | -1.32 M | -1.13 M | - | -832 K | -1.38 M | -1.41 M | - | -569 K | -988 K | -1.06 M | - | -1.18 M | -1.08 M | -1.12 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -569 K | -9.56 M | -3.22 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Electromed
ELMD
|
10.7 M | $ 25.1 | - | $ 212 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.98 | - | $ 1.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 13.08 | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.03 | - | $ 17.4 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 14.64 | - | $ 343 M | USA |
 |
LivaNova PLC
LIVN
|
228 M | $ 58.92 | - | $ 3.21 B |  Britain |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.31 | - | $ 124 M |  France |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Insulet Corporation
PODD
|
564 M | $ 160.02 | - | $ 11.3 B | USA |
 |
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.99 | - | $ 5.52 M | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 10.34 | - | $ 293 M | USA |
 |
Stryker Corporation
SYK
|
6.46 B | $ 315.13 | - | $ 120 B | USA |
 |
Tactile Systems Technology
TCMD
|
35.9 M | $ 22.5 | - | $ 515 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 0.86 | - | $ 40.4 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
TransMedics Group
TMDX
|
136 M | $ 98.57 | - | $ 3.35 B | USA |
 |
Tandem Diabetes Care
TNDM
|
26 M | $ 18.16 | - | $ 1.24 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Varex Imaging Corporation
VREX
|
-4.6 M | $ 11.03 | - | $ 457 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Vivos Therapeutics
VVOS
|
-18.6 M | $ 0.78 | - | $ 8.01 M | USA |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 4.92 | - | $ 1.04 B | USA |
 |
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
757 M | $ 87.79 | - | $ 11.9 B | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 10.21 | - | $ 366 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 35.96 | - | $ 1.12 B | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 53.41 | - | $ 1.57 B | USA |
 |
Integer Holdings Corporation
ITGR
|
352 M | $ 83.67 | - | $ 2.91 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.22 | - | $ 47.5 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |